TABLE I. Characteristics of 31 patients with cutaneous leishmaniasis treated with intralesional meglumine antimoniate, Centro de Pesquisas René Rachou - Fundação Oswaldo Cruz (Fiocruz), Belo Horizonte, Minas Gerais, Brazil, 2016.
| Characteristic | Median (IR) |
|---|---|
| Age (years) | 63 (41-76) |
| Lesion length before treatment (IR, weeks) | 16 (8-28) |
| Lesion size (cm2) | 1.7 (0.8-6.6) |
| Gender | n (%) |
| Male | 15 (48) |
| Female | 16 (52) |
| Disease type | n (%) |
| Primary cutaneous leishmaniasis | 27 (87) |
| Relapsed cutaneous leishmaniasis | 4 (13) |
| Number of lesions per patient | n (%) |
| one | 22 (70.9) |
| two | 6 (19.4) |
| three | 3 (9.7) |
| Lesion location | n (%) |
| Head/neck | 10 (32.3) |
| Arms/hand | 10 (32.3) |
| Leg | 7 (22.6) |
| Chest/back | 4 (12.9) |
| Lesion type | n (%) |
| Ulcer | 17 (54.8.0) |
| Papule | 8 (25.8) |
| Plate | 6 (19.4) |
| Intralesional therapy indication | n (%) |
| Systemic antimony contra-indication | 18 (58.1) |
| Previous systemic antimony treatment failure | 5 (16.1) |
| Serious adverse event with systemic antimony | 4 (12.9) |
| Social or logistic reasons | 4 (12.9) |
| Systemic antimony contra-indications* | n (%) |
| Elderly | 13 (41.9) |
| Heart disease | 10 (32.2) |
| Renal disease | 6 (19.4) |
| Alcohol abuse | 2 (6.5) |
| Enlarged QTc interval | 2 (6.5) |
| Continuous use of medications that extend QTc interval | 1 (3.2) |
| Liver disease | 1 (3.2) |
IR: interquartile range (25-75%); *: some patients presented more than one contraindication condition.